Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 30 Results

Title
Intervention Indication Therapeutic Area Year Actions
177Lu-PSMA-617 for metastatic castrationresistant prostate cancer - third line Lutetium (177Lu-PSMA-617; 177Lu-DOTA-tyr3-octreotate; Lutathera) Prostate cancer Male Reproductive Cancer 2020 View  |  Download
Abemaciclib with abiraterone acetate and prednisone for metastatic castration-resistant prostate cancer Abemaciclib (LY2835219; Verzenio; CC-115) , Abiraterone acetate (Zytiga; Yonsa) , Prednisone (Decadron; Lodotra) Prostate cancer Male Reproductive Cancer 2022 View  |  Download
Apalutamide for treating high-risk, localised or locally advanced prostate cancer Apalutamide (Erleada; ARN-509) Prostate cancer Male Reproductive Cancer 2023 View  |  Download
Apalutamide in Addition to Abiraterone and Prednisone/Prednisolone for Metastatic Castration-resistant Prostate Cancer – First Line Abiraterone acetate (Zytiga; Yonsa) , Apalutamide (Erleada; ARN-509) , Prednisone (Decadron; Lodotra) Prostate cancer Male Reproductive Cancer 2018 View  |  Download
Apalutamide in addition to androgen deprivation therapy for metastatic hormone-sensitive prostate cancer Apalutamide (Erleada; ARN-509) Prostate cancer Male Reproductive Cancer 2018 View  |  Download
Apalutamide with primary radiation therapy for treating high-risk, localised or locally advanced prostate cancer Apalutamide (Erleada; ARN-509) , Primary radiation therapy Prostate cancer Male Reproductive Cancer 2022 View  |  Download
Atezolizumab with cabozantinib for previously treated metastatic castration-resistant prostate cancer Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) Prostate cancer Male Reproductive Cancer 2022 View  |  Download
Cabozantinib with atezolizumab for treating metastatic castration-resistant prostate cancer after one novel hormonal therapy Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) Prostate cancer Haematological Cancer and Lymphomas , Oncology 2023 View  |  Download
Darolutamide for Non‐metastatic, Castration-resistant Prostate Cancer Darolutamide (ODM-201; BAY-1841788; Nubeqa) Prostate cancer Male Reproductive Cancer 2018 View  |  Download
Darolutamide in addition to docetaxel and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer Darolutamide (ODM-201; BAY-1841788; Nubeqa) , Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) Prostate cancer Male Reproductive Cancer 2021 View  |  Download
1 2 3
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications